Pentoxifylline in Diabetic Kidney Disease

A phase 4 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 2376 participants.

Also called NCT03625648

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 2,376 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03625648
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT03625648. Randomized; quadruple masking; primary purpose treatment. Start 2019-11-18 (actual); primary completion 2028-01-03 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Pentoxifylline in Diabetic Kidney Disease
Acronym
VA PTXRx
Condition
Diabetic Kidney Disease
Intervention (Drug)
Pentoxifylline
Intervention (Drug)
Placebo
Lead sponsor
VA Office of Research and Development (class: US federal agency)

Record details

Record id
cardio:ct-nct03625648
Content hash
fa6e8c0225665aac6c6329a937f9933d10f187cedd4f3b8aebf8302c69d28b63